SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 227 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.34 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,316,027 | -34.6% | 47,734 | -14.1% | 0.00% | 0.0% |
| Q2 2023 | $2,013,736 | 0.0% | 55,582 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $2,013,736 | -1.2% | 55,582 | -2.7% | 0.00% | 0.0% |
| Q4 2022 | $2,038,254 | -99.9% | 57,142 | -2.6% | 0.00% | 0.0% |
| Q3 2022 | $1,986,894,000 | +30.6% | 58,697 | +11.5% | 0.00% | 0.0% |
| Q2 2022 | $1,521,799,000 | -12.1% | 52,621 | -1.8% | 0.00% | 0.0% |
| Q1 2022 | $1,731,221,000 | +35.0% | 53,565 | +21.8% | 0.00% | – |
| Q4 2021 | $1,282,339,000 | +6.2% | 43,976 | -2.9% | 0.00% | -100.0% |
| Q3 2021 | $1,207,752,000 | -13.4% | 45,285 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,394,324,000 | +24.9% | 45,285 | +6.2% | 0.00% | – |
| Q1 2021 | $1,116,054,000 | +4.1% | 42,630 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $1,072,570,000 | +20.7% | 42,630 | 0.0% | 0.00% | – |
| Q3 2020 | $888,410,000 | -12.3% | 42,630 | 0.0% | 0.00% | -100.0% |
| Q2 2020 | $1,012,464,000 | +81.6% | 42,630 | +37.6% | 0.00% | – |
| Q1 2020 | $557,457,000 | -42.8% | 30,987 | -24.6% | 0.00% | -100.0% |
| Q4 2019 | $974,914,000 | -25.6% | 41,101 | -13.8% | 0.00% | 0.0% |
| Q3 2019 | $1,309,916,000 | -1.2% | 47,668 | +19.0% | 0.00% | 0.0% |
| Q2 2019 | $1,325,619,000 | -77.8% | 40,061 | -76.5% | 0.00% | -75.0% |
| Q1 2019 | $5,962,406,000 | +6.9% | 170,160 | +1.3% | 0.00% | -20.0% |
| Q4 2018 | $5,577,472,000 | -37.5% | 167,895 | -5.2% | 0.01% | -28.6% |
| Q3 2018 | $8,920,560,000 | -12.0% | 177,171 | +4.6% | 0.01% | -12.5% |
| Q2 2018 | $10,137,633,000 | +21.9% | 169,384 | -6.7% | 0.01% | +14.3% |
| Q1 2018 | $8,315,309,000 | -13.4% | 181,557 | -24.7% | 0.01% | -12.5% |
| Q4 2017 | $9,606,879,000 | -2.6% | 241,076 | -2.2% | 0.01% | -11.1% |
| Q3 2017 | $9,862,840,000 | +14.5% | 246,571 | +23.4% | 0.01% | +12.5% |
| Q2 2017 | $8,612,156,000 | +1451.3% | 199,818 | +1026.6% | 0.01% | +700.0% |
| Q1 2017 | $555,168,000 | +219334.0% | 17,737 | +77.4% | 0.00% | – |
| Q4 2016 | $253,000 | -41.2% | 10,000 | -42.5% | 0.00% | – |
| Q3 2016 | $430,000 | +20.8% | 17,400 | -0.6% | 0.00% | – |
| Q2 2016 | $356,000 | +33.3% | 17,500 | 0.0% | 0.00% | – |
| Q1 2016 | $267,000 | +4.7% | 17,500 | -7.9% | 0.00% | – |
| Q4 2015 | $255,000 | -4.5% | 19,000 | 0.0% | 0.00% | – |
| Q3 2015 | $267,000 | -17.3% | 19,000 | 0.0% | 0.00% | – |
| Q2 2015 | $323,000 | – | 19,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |